title: Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics.
abstract: Technical advances made in the 1980s and early 1990s resulted in monoclonal antibodies that are now approved for human therapy. Novel transgenic mouse strains provide a powerful technology platform for creating fully human monoclonal antibodies as therapeutics; ten such antibodies have entered clinical trials since 1998 and more are in preclinical testing. Improved transgenic mouse strains provide a powerful technology platform for creating human therapeutics in the future.
authors.affiliation: Abgenix, Inc., 6701 Kaiser Drive, Fremont, CA 94555, USA.
authors.forename: Sirid Aimée
authors.initials: SA
authors.lastname: Kellermann
authors.forename: Larry L
authors.initials: LL
authors.lastname: Green
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000276:immunology / Q000627:therapeutic use*; D005803:Genes, Immunoglobulin; D006801:Humans; D007128:Immunoglobulin Fragments / Q000096:biosynthesis / Q000276:immunology / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007128:Immunoglobulin Fragments